SCHEMBL1930180

SCHEMBL1930180

CC(CN)(NCCc1ccccc1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
TAAR1 Q96RJ0 3/20 0.46
CYP1A2 P05177 3/20 0.46
CYP3A4 P08684 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.46
CYP2D6 P10635 2/20 0.46
ATM Q13315 1/20 0.46
KDM1A O60341 1/20 0.46
HTR1A P08908 1/20 0.46
ADRA2A P08913 1/20 0.46
CYP2C8 P10632 1/20 0.46
CYP2C9 P11712 1/20 0.46
IDO1 P14902 1/20 0.46
TSHR P16473 1/20 0.46
NFKB1 P19838 1/20 0.46
MAOA P21397 1/20 0.46
PTGS1 P23219 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29193469 0.80 NPC1 (0.50) NPC1RAB9ATAAR1CYP1A2CYP3A4
SCHEMBL1887928 0.79 CYP2C19 (0.50) NPC1RAB9ACYP1A2CYP3A4SMN1; SMN2
SCHEMBL29193474 0.79 SMN1; SMN2 (0.48) NPC1RAB9ATAAR1CYP1A2CYP3A4
SCHEMBL6231282 0.78 ATM (0.52) NPC1RAB9ATAAR1CYP1A2CYP3A4
SCHEMBL1640060 0.75 ATM (0.58) NPC1RAB9ATAAR1CYP1A2CYP3A4
SCHEMBL28333330 0.74 TAAR1 (0.56) TAAR1CYP1A2CYP3A4SMN1; SMN2LMNA
SCHEMBL11708887 0.72 SIGMAR1 (0.46) NPC1RAB9ATAAR1CYP1A2CYP3A4
SCHEMBL11636072 0.71 TAAR1 (0.44) NPC1RAB9ATAAR1CYP1A2CYP3A4
SCHEMBL21058251 0.71 ATM (0.52) NPC1RAB9ATAAR1CYP1A2CYP3A4
SCHEMBL19334561 0.71 ATM (0.52) NPC1RAB9ATAAR1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7956219-B2 Amino acid analogues Baker IDI Heart and Diabetes (AU) 2011-06-07 US disclosed
EP-1501791-B1 AMINO ACID ANALOGUES BAKER MED RES INST (AU) 2009-01-21 EP disclosed
US-20060094902-A1 Amino acid analogues BAKER IDI HEART AND DIABETES INSTITUTE HOLDINGS LTD. (AU) 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094902-A1 Amino acid analogues EDNRB, EDNRA, NOS2 NPC1 4046/4885RAB9A 1511/4885TAAR1 3069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.